cagrilintide clinical trials results New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Weight loss medicine is entering

Key Benefits Rapid Bioavailability Intramuscular or slow IV administration bypasses gastrointestinal limits for immediate plasma levels

Copper labs are context-specific and are not needed for every casual skin-care discussion

How long this lasts depends on how well the patient responds and the severity of the deficiency

What Sponsors Should Actually Do The fixes that recur across current industry and peer-reviewed sources are architectural, not incremental: Build Quality by Design into study design from day one, so decentralized elements are explicitly defined and operationalizable within an investigator's existing governance not added after the protocol is finalized